



BANDARAM PHARMA PACKTECH LIMITED

CIN: L93090KA1993PLC159827

To,

Date: 14.11.2024

BSE Limited

P.J.Towers, Dalal Street

Mumbai - 400001

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on 14.11.2024 under Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015.

Unit: Bandaram Pharma Packtech Limited (BSE Scrip code: 524602)

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Bandaram Pharma Packtech Limited held on Thursday, 14.11.2024 at 04:30 p.m. at the Registered Office of the Company situated at 601, 5th Floor, Oxford Towers, Opp to Leela Palace Hotel, Old Airport Road, Kodihalli Bangalore- 560008, Karnataka the following were considered and approved:

1. Un-audited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30.09.2024. **(Enclosed)**
2. Limited Review Report (standalone and consolidated) as per Regulation 33 of SEBI (LODR) Regulations, 2015 for the quarter and half year ended 30.09.2024. **(Enclosed)**

Regd. & Corporate Office: Oxford Towers, Unit No. 601, 5th floor, Opp. to Leela Palace Hotel,
Old Airport Road, Kodihalli, Bangalore-560008

Ph No.: 9900002025, E-mail: info.bandaram@gmail.com



BANDARAM PHARMA PACKTECH LIMITED

CIN: L93090KA1993PLC159827

The meeting concluded at 05:30 p.m.

Thanking you.

Yours sincerely,

For Bandaram Pharma Packtech Limited

B Deepak
Reddy

Digitally signed by B
Deepak Reddy
Date: 2024.11.14
17:39:30 +05'30'

B. Deepak Reddy
Managing Director
DIN: 07074102

Encl: as above

	(ii) Income tax on items that may be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	-	-
	Total Comprehensive Income	-	-	-	-	-	-	-	-	-	-	-	-
XV	Total Comprehensive Income for the	33.08	(24.86)	5.49	8.22	11.06	12.84	#REF!	17.83	11.88	#REF!	19.34	94.77
XVI	Earnings Per Equity Share of face value of Rs.10/- each)(for Countinuing opertions):												
	1) Basic	0.28	(0.21)	0.05	0.07	0.37	0.11	#REF!	0.15	0.10	#REF!	0.16	0.79
	2) Diluted	0.28	(0.21)	0.05	0.07	0.37	0.11	#REF!	0.15	0.10	#REF!	0.16	0.79
XVII	Earnings Per Equity Share of face value of Rs.10/- each) (for Discountinuing												
	1) Basic	0.28	(0.21)	0.05	0.07	0.37	0.11	#REF!	0.15	0.10	#REF!	0.16	0.79
	2) Diluted	0.28	(0.21)	0.05	0.07	0.37	0.11	#REF!	0.15	0.10	#REF!	0.16	0.79
XVIII	Earnings Per Equity Share of face value of Rs.10/- each) (for Continued and Discountinuing opertions):												
	1) Basic	0.28	(0.21)	0.05	0.07	0.37	0.11	#REF!	0.15	0.10	#REF!	0.16	0.79
	2) Diluted	0.28	(0.21)	0.05	0.07	0.37	0.11	#REF!	0.15	0.10	#REF!	0.16	0.79
XIX	Paid-up equity share capital (Face Value of Rs. 10/- per share)	1,200.00	1,200.00	1,200.00	1,200.00	1,200.00	1,200.00	1,200.00	1,200.00	1,200.00	1,200.00	1,200.00	1,200.00

Notes:

- 1.. In pursuance with Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III of the Companies Act, 2013, the above Financial Results have been prepared. The same is reviewed by the Statutory Auditors of Company and recommended by the Audit Committee and subsequently approved by the Board of Directors of Company at their meeting held on -07-2022.
2. The Financial Statements have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS-34 "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under and other accounting propouncements generally accepted in India.
3. The figures of the previous year/periods have been re-grouped/re-classified, wherever necessary, for the purpose of comparison with the current year/period figures.
4. Segmentwise reprot as per Ind AS -108 , is not applicable.
5. Income-tax/Deffered tax liabilitis for the current period will be determined at th end of the accounting year.
- 6.The above Financial Results are also available on the company's webiste www.bandaram.com
7. The Consolidated Results includes M/s VSR Paper and Packaging Limited

For and on Behalf of the Board of Directors
Bandaram Pharma Packtech Limited
(Formerly Known as Shiva Medicare Limited)

B. Deepak Reddy
Managing Director
DIN: 07074102



Place : Bangalore
Date : 14-11-2024

Bandaram Pharma Packtech Limited
(Formerly Known as Shiva Medicare Limited)
CIN: L93090KA1993PLC159827

Regd Office: 601, 5th Floor, Oxford Towers, Opp. to Leela Palace Hotel, Old Airport Road, Kodihalli, Bangalore - 560008.

UN-AUDITED STANDALONE CASH FLOW STATEMENT FOR THE YEAR ENDED 30th September, 2024


Particulars	30-09-2024	31-03-2024
		(₹)
A. CASH FROM OPERATING ACTIVITIES		
(Loss)/Profit before tax and extraordinary items	8.22	17.12
Adjustment for:		
Finance costs recognised in profit or loss	0.00	0.00
Depreciation and amortisation of non-current assets	0.37	1.54
Impairment of non-current assets	0	-
Net foreign exchange (gain)/loss	0	-
Operating Profit before Working Capital Changes	8.59	18.66
Movement for Working Capital:		
(Increase)/ decrease in trade and other receivables	-475.61	(20.90)
(Increase)/decrease in inventories	193.07	(160.85)
(Increase)/ decrease in Short term loans & advances	88.86	(152.03)
(Increase)/decrease in other assets	10.44	(40.49)
Increase/ (Decrease) in trade and other payables	-35.36	43.55
Increase/(decrease) in provisions	0	-
(Increase)/ decrease in other non current assets	-	(0.50)
(Decrease)/increase in Current liabilities	7.49	(8.90)
CIRP Expenses	0	-
Cash generated from operations	(202.52)	(321.46)
- Income taxes paid	0	4.28
Net Cash flow before extraordinary items	(202.52)	(325.74)
-Extraordinary & Prior period items		-
NET CASH FROM OPERATING ACTIVITIES	(202.52)	(325.74)
B. CASH FLOW FROM INVESTING ACTIVITIES:		
Particulars	30-09-2024	31-03-2024
B. CASH FLOW FROM INVESTING ACTIVITIES:		
Payments to acquire financial assets		-
Interest received		-
Dividends received from associates		-
Proceeds / (Repayment) of Loans & advances		-
Amounts advanced to related parties		-
Repayments by related parties		-
Payments for property, plant and equipment		-
Proceeds from disposal of property, plant and equipment		-
Payments for investment property	0	(140.00)
Proceeds from long term liabilities		-
Payments for intangible assets		-
Net cash outflow on acquisition of subsidiaries		-
Net cash inflow on disposal of subsidiary		-
Net cash inflow on disposal of associate		-
NET CASH FROM INVESTING ACTIVITIES	0	(140.00)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Particulars		31-03-2024
CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from issue of equity instruments of the Company	0	900.00
Proceeds from issue of convertible notes		-
Proceeds from issue of redeemable preference shares		-
Payment for debt issue costs Proceeds from borrowings		-
Repayment of borrowings		(438.75)
Increase in Long term borrowings	200.00	-
Dividends paid on redeemable cumulative preference shares		-
Dividends paid to owners of the Company		-
Interest paid		(0.00)
Long Term Provisions		-
Provision for Capital Gain Tax		-
NET CASH FROM FINANCING ACTIVITIES	200.00	461.25
NET INCREASE IN CASH & CASH EQUIVALENTS	(2.52)	(4.49)

Cash and cash equivalents at the beginning of the year	4.04	8.52
Cash and cash equivalents at the end of the year	1.52	4.03
Reconciliation of cash and cash equivalents as per the cash flow Statement		
Cash and cash equivalents (Note. 4)	1.52	4.04
Balance as per statement of cash flows	1.52	4.04

Corporate Information and Significant Accounting Policies & Notes to Accounts are given in Note 1 and Note 2.

The notes referred above, form an integral part of the Financial Statements.

For and on behalf of the Board of Directors
Bandaram Pharma Packtech Limited
(Formely Known as Shiva Medicare Limited)



B. Deepak Reddy
Managing Director
DIN: 07074102



Place: Bangalore
Date: 14-11-2024

Bandaram Pharma Packtech Limited
(Formerly Known as Shiva Medicare Limited)
CIN: L93090KA1993PLC159827

Regd Office: 601,5th Floor, Oxford Towers, opp to Leela Palace Hotel, Old Airport Road, Kodihalli Bangalore - 560008

Un-Audited Statement of Financial Position as at September 30, 2023

(Amt. Rs. In Lakhs)

	Particulars	As at September 30, 2024	As at March 31, 2024
I	ASSETS		
1	Non-current assets		
	(a) Property, plant and equipment	0.53	0.90
	(b) Right to use assets		
	(c) Capital work in progress		
	(d) Investments	390.82	390.82
	(e) Other non-current asset	0.50	0.50
	Total non-current assets (A)	391.85	392.22
2	Current assets		
	(a) Inventories	22.76	215.83
	(b) Financial assets		
	(i) Cash and cash equivalents	1.52	4.04
	(ii) Bank Balances other than (i) above		
	(iii) Trade Receivables	765.65	290.04
	(c) Current Tax Asset (Net)		
	(d) Short-term loans & Advances	182.35	271.21
	(e) Other current assets	151.76	162.19
	Total current assets (B)	1,124.04	943.31
	Total assets (A+B)	1,515.89	1,335.53
II	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity share capital	1,200.00	1,200.00
	(b) Other equity	28.47	20.24
	Total equity (A)	1,228.47	1,220.24
2	Liabilities		
(i)	Non-current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	201.75	1.75
	(ii) Trade Payables	-	-
	(b) Long term liability	-	-
	(c) Deferred tax Liabilities(Net)		
	(d) Other non Current Liabilities		
	Total non-current liabilities (B)	201.75	1.75
(ii)	Current liabilities		
	(a) Financial liabilities		
	(i) Borrowings	-	-
	(ii) Trade payables	63.52	98.88
	(b) Other current liabilities	17.87	10.38
	(c) Current Tax Laibilities (net)	4.28	4.28
	Total current liabilities (C)	85.67	113.54
	Total liabilities (D=B+C)	287.42	115.29
	Total equity and liabilities (A+D)	1,515.89	1,335.53

For and on behalf of the Board of Directors
Bandaram Pharma Packtech Limited
(Formerly Known as Shiva Medicare Limited)

B. Deepak Reddy
Managing Director
DIN: 07074102



Place: Bangalore
Date: 14-11-2024

Bandaram Pharma Packtech Limited
(Formerly Known as Shiva Medicare Limited)
CIN:L93090KA1993PLC159827

Regd Office: 601, 5th Floor, Oxford Towers, Opp. to Leela Palace Hotel, Old Airport Road, Kodihalli, Bangalore - 560008.

STATEMENT OF UN-AUDITED CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED SEPTEMBER 31, 2024

(Rs. In Lakhs)

PARTICULARS	Consolidated As at September 30,2024	Consolidated As at March 31,2024
A. CASH FLOW FROM OPERATING ACTIVITIES :		
Net profit before tax	-	118.66
Adjustment for:		-
Depreciation and Amortisation	30.36	71.38
Preliminary Expenses Written off		-
Interest Earned		-
Interest & Finance Charges	47.26	94.97
Operating Profit before Working Capital Changes	77.62	285.01
Movements in Working Capital:		
Decrease/(Increase) in Inventories	-376.96	(235.71)
Decrease/(Increase) in Trade Receivables	79.12	(945.44)
Decrease/(Increase) in Short term loans & advances	88.86	73.87
Decrease/(Increase) in Other Current Assets	15.43	(69.49)
Increase/ (Decrease) in trade and other payables	-162.33	403.49
Increase/(Decrease) in Provisions	0.00	17.60
Increase/(Decrease) in Short term borrowings	59.08	97.12
Increase/(Decrease) in Other current liabilities	10.87	(14.20)
Increase/(Decrease) in Trade Payables	0	-
Change in Working Capital	(208.31)	(387.75)
Changes in non current assets and liabilities		
Decrease/(Increase) in loans & advances		(3.20)
Decrease/(Increase) in Long Term Provisions		-
Decrease/(Increase) in Other non Current Assets	-2.90	(0.11)
Changes in non current assets and liabilities	(2.90)	(3.31)
Cash Generated From Operations	(211.21)	(391.07)
Less: Taxes paid		21.88
Net Cash from operating activities(A)	(211.21)	(412.95)
B. CASH FLOW FROM INVESTING ACTIVITIES		

Payments for property, plant and equipment		(17.90)
Payments for investment property		(140.00)
Interest Received		-
Proceeds from long term liabilities		-
Other Investment		-
Long Term Assets		-
-Balance of Unclaimed Dividend		
Net cash used in Investing activities (B)	-	(157.90)
C.CASH FLOW FROM FINANCING ACTIVITIES		
Increase / (Decrease) in Share Capital		900.00
Increase / (Decrease) in Borrowings	185.23	(247.19)
Increase/(Decrease) in Minority Interest		-
Interest paid	-47.26	(93.43)
Net cash Flow from Financing Activities (C)	137.97	559.37
Net Increase/(Decrease) in cash & cash equivalents [A+B+C]	(73.24)	(11.48)
CASH & CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	4.21	15.69
CASH & CASH EQUIVALENTS AT THE END OF THE YEAR	(69.03)	4.21

Corporate Information and Significant Accounting Policies & Notes to Accounts are given in Note no.1 and Note No. 2.

The notes referred above, form an integral part of the Financial Statements.

For and on behalf of the Board of Directors
Bandaram Pharma Packtech Limited
(Formely Known as Shiva Medicare Limited)

B. Deepak Reddy
Managing Director
DIN: 07074102



Place: Bangalore
Date: 14-11-2024

Bandaram Pharma Packtech Limited
(Formerly Known as Shiva Medicare Limited)
CIN: L93090KA1993PLC159827

**Regd Office: 601,5th Floor, Oxford Towers, opp to Leela Palace Hotel, Old Airport Road,
Kodihalli Bangalore - 560008**

UN-AUDITED CONSOLIDATE BALANCE SHEET AS AT 30TH SEPTEMBER 2024

(Amount in lakhs)

	PARTICULARS	As at September 30, 2024	As at March 31, 2024
I	<u>ASSETS:</u>		
(1)	Non-current assets		
	(a) Property, Plant and Equipment	418.07	448.43
	(b) Right of Use Assets	-	
	(c) Capital work-in-progress	-	
	(d) Investment Property	-	
	(e) Goodwill	-	
	(f) Other Intangible Assets	-	
	(g) Intangible Assets under development	-	-
	(h) Biological Assets	-	-
	(i) Financial assets	-	-
	(i) Investments	139.99	140.00
	(ii) Trade Receivables	-	-
	(iii) Loans & Advances	-	-
	(iv) Other Financial Assets	-	-
	(j) Deferred tax assets (net)	-	-
	(k) Other non-current assets	13.75	10.85
	SUB TOTAL	571.81	599.28
(2)	Current assets		
	(a) Inventories	1,023.76	646.80
	(b) Financial assets	-	
	(i) Investments	-	
	(ii) Trade receivables	1,373.02	1,452.14
	(iii) Cash and cash equivalents	15.99	4.21
	(iv) Bank Balances other than (iii) above	-	
	(v) Loans and advances	132.35	221.21
	(vi) Investments held for Sale	-	
	(c) Current Tax Asset Net	-	
	(d) Other current assets	266.66	282.08
	SUB TOTAL	2,811.78	2,606.44
	Non-Current Assets Classified as held for Sale	-	
		-	
	TOTAL ASSETS	3,383.60	3,205.72
II	<u>EQUITY AND LIABILITIES:</u>		
	Equity		
	(a) Equity Share Capital	1,200.00	1,200.00
	(b) Other Equity	-	
	(ii) Reserves and Surplus	115.35	28.02
	© Share Application money pending allotment	-	
	Minority Interest	276.31	278.62
		1,591.66	1,506.64
	Liabilities		
(1)	Non Current Liabilities		
	(a) Financial Liabilities	-	
	(i) Borrowings	652.77	467.54
	(ii) Trade Payables	-	-
	(iii) Other financial liabilities	-	-
	(b) Provisions	-	-
	(i) Provision for Employee benefit	-	-
	(ii) Others	-	-

	(c) Deferred tax liabilities (Net)	7.98	7.98
	(d) Other non Current Liabilities	-	-
		660.75	475.52
(2)	Current Liabilities	-	-
	(a) Financial Liabilities	-	-
	(i) Borrowings	811.70	752.62
	(ii) Trade Payables	249.49	411.82
	(iii) Other financial liabilities	-	-
	(b) Other current liabilities	48.11	37.24
	(c) Provisions	21.88	21.88
	(d) Current tax liabilities(Net)	-	-
		1,131.18	1,223.56
	TOTAL EQUITY AND LIABILITIES	3,383.60	3,205.72

For and on behalf of the Board of Directors
Bandaram Pharma Packtech Limited
(Formely Known as Shiva Medicare Limited)

Deepak Reddy
B. Deepak Reddy
Managing Director
DIN: 07074102



Place: Bangalore
Date: 14-11-2024



M M REDDY & CO.,
Chartered Accountants

M M R Lion Corp, 4th Floor, HSR Eden, Beside Cream Stone, Road No.2, Banjara Hills, Hyderabad 500034 Telangana

LIMITED REVIEW REPORT

To,
The Board of Directors,
BANDARAM PHARMA PACKTECH LIMITED

We have reviewed the accompanying statement of Un-Audited Standalone Financial Results of **BANDARAM PHARMA PACKTECH LIMITED (formerly known as Shiva Medicare Limited)** for the quarter ended **30th September, 2024** attaching herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations and disclosure Requirements) Regulations, 2015, as amended.

The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standard) Rules, 2015 is the responsibility of the company management and has been approved by the Board of Directors of the Company. Our Responsibility is to express a conclusion on the statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information performed by the Independent auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M M REDDY & CO.,
Chartered Accountants
Firm Regn No 010371S

MADHUSUDHAN A REDDY
Partner
Date: 2024.11.14
Membership No 213077

Place: Hyderabad
Date: 14-11-2024

UDIN: 24213077BKBHOT6310



M M REDDY & CO.,

Chartered Accountants

M M R Lion Corp, 4th Floor, HSR Eden, Beside Cream Stone, Road No.2, Banjara Hills, Hyderabad 500034 Telangana

Independent Auditor's Review Report on Interim Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

Board of Directors of

M/s. BANDARAM PHARMA PACKTECH LIMITED

We have reviewed the quarterly Consolidated Unaudited Financial Results of **BANDARAM PHARMA PACKTECH LIMITED (formerly known as Shiva Medicare Limited)** ("The Company") and its subsidiaries (Collectively referred to as Group) for the quarter ended 30th September, 2024 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

These quarterly consolidated financial results as well have been prepared on the basis of the consolidated interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these Consolidated financial results based on our audit of such Consolidated interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our review of the Statement in accordance with the standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity," issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance

that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Attention is drawn to the statement which states that the Consolidated figures for the Corresponding quarters ended September 30,2023 and June 30, 2024 as reported in the accompanying Statement have been approved by the Parent's Board of Directors, but have not been subjected to review.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.

We did not review the interim financial information of Subsidiary company which are included in the consolidated quarterly unaudited financial results, whose consolidated interim financial information reflects, total revenues of VSR Paper and Packaging Limited is Rs. 687.90 Lakhs for the quarter ended 30th September, 2024, total net profit of VSR Paper and Packaging Limited is Rs. 34.11 Lakhs and total comprehensive income/(loss) of VSR Paper and Packaging Limited is Rs.34.11 Lakhs for the quarter ended September 30, 2024. These interim financial information has been reviewed by other Auditors whose reports have been furnished to us by management and our conclusion on the statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, based solely on the reports of the other auditors.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results:

- I. Include the quarterly financial results of the following entities: -
 - a) VSR Paper and Packaging Limited (Holding 55%)
- II. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard;

For M M REDDY & CO.,
Chartered Accountants
Firm Regn No.010371S

Date: 14-11-2024
Place: Hyderabad

MADHUSU Digitally signed
by
DHANA MADHUSUDHANA REDDY
M. Madhusudhana Reddy
REDDY A REDDY MALIGI
Partner Date: 2024.11.14
MALIGI 15:46:30 +05'30'
Membership No.213077

UDIN: 24213077BKBHOU8174